Karyopharm Therapeutics Inc. (KPTI)

Market Cap	135.37M
Revenue (ttm)	140.46M
Net Income (ttm)	-146.34M
Shares Out	117.71M
EPS (ttm)	-1.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,448,320
Open	1.150
Previous Close	1.135
Day's Range	1.125 - 1.190
52-Week Range	0.617 - 2.670
Beta	0.15
Analysts	Buy
Price Target	4.80 (+317.39%)
Earnings Date	May 8, 2024

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2013
• Employees: 325
• Stock Exchange: NASDAQ
• Ticker Symbol: KPTI

Financial Performance

In 2023, KPTI's revenue was $146.03 million, a decrease of -7.03% compared to the previous year's $157.07 million. Losses were -$143.10 million, -13.43% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price forecast is $4.8, which is an increase of 317.39% from the latest price.

Price Target

$4.8

(317.39% upside)

Analyst Consensus: Buy